Odds of Prescribing Drugs Up With Doc Receipt of Payments

Share this content:
Odds of Prescribing Drugs Up With Doc Receipt of Payments
Odds of Prescribing Drugs Up With Doc Receipt of Payments

WEDNESDAY, April 11, 2018 (HealthDay News) -- Physicians receiving general payments from pharmaceutical companies are more likely to prescribe their drugs, according to a research letter published online April 9 in JAMA Internal Medicine.

Aaron P. Mitchell, M.D., from the University of North Carolina at Chapel Hill, and colleagues examined the correlation between oncologists' receipt of payments from pharmaceutical manufacturers and drug selection in two situations where multiple treatment options exist. The two sets of drugs were sorafenib, sunitinib malate, and pazopanib hydrochloride for metastatic renal cell cancer (mRCC) and dasatinib, imatinib mesylate, and nilotinib hydrochloride monohydrate for chronic myeloid leukemia (CML). Data were included for 354 physicians who prescribed the mRCC drugs and 2,225 physicians who prescribed the CML drugs; physicians had at least 20 filled prescriptions among the three drugs in 2014.

The researchers found that the odds of prescribing a manufacturer's drug were increased among physicians receiving general payment only or either payment type (general or research). For mRCC, but not CML, receipt of research payments was associated with increased prescribing. Considering individual drugs, increased prescribing was seen for receiving versus not receiving general payments for sunitinib, dasatinib, and nilotinib; decreased prescribing of imatinib was seen. The differences were not statistically significant for sorafenib and pazopanib. Research payments were not correlated with any statistically significant differences in prescribing for individual drugs.

"For three of the six cancer drugs studied, physicians who received general payments were more likely to prescribe the drug marketed by the company that made the payments," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »